B2Gold has been rated a cautious Buy following a roughly 50% rally, supported by the approval of its Mali expansion and the upcoming end of hedges, which will allow more profitable spot gold sales. Key future drivers include an expected cash flow improvement in the second half of 2027, strong shareholder returns with a floor of about 7%, and lower all-in sustaining costs as new projects increase production. The company's valuation is near historical averages but discounted due to risks related to West Africa exposure and production concentration. The investment outlook depends on gold prices holding around $4,000 per ounce and successful project execution, with opportunities to buy on price dips.
B2Gold's recent cautious Buy rating comes as a backdrop to today's broad market activity on Pluang. For readers following US stocks, here is Pluang's market snapshot as of Sep 17, 2026 19:44 WIB: out of 150 priced US stocks, 129 rose and 19 fell. Notably, Moderna (MRNA) gained 4.90% with a Pluang order activity skewed 67% Buy and a typical hold time of 60 days, contrasting with Marvell Technology (MRVL) which rose 4.41% but saw 78% Sell orders and a shorter hold time of 40 days. Affirm Holdings (AFRM) also rose 4.22% with a typical hold time of 21 days.
Miracles, a personalized children's book maker, has printed more than 100,000 books, serving over 45,000 families. Each book features a unique 3D character of the child, created from a single photo, making the child the hero of the story. Books for U...
Miracles, a company specializing in personalized children's books where each child becomes the story's hero, has printed over 100,000 books for more than 45,000 families. The books are printed locally in Germany and delivered within a few days, offer...
The global migraine market is projected to expand at a 6% annual growth rate through 2036, driven by rising migraine prevalence, better diagnosis, and awareness. Innovative treatments beyond traditional CGRP inhibitors, including PACAP-targeted thera...
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
